139 related articles for article (PubMed ID: 37202829)
1. In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration.
Wang XK; Yu J; Xie CY; Hu XX; Nie TY; Li X; Wang PH; Li GQ; Yuan H; Yang XY; Li CR; You XF
J Antimicrob Chemother; 2023 Jul; 78(7):1632-1636. PubMed ID: 37202829
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Wang W; Voss KM; Liu J; Gordeev MF
Chem Res Toxicol; 2021 May; 34(5):1348-1354. PubMed ID: 33913699
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Antibacterial Contezolid Acefosamil: Innovative
Liu J; Wang W; Wang C; Zhang L; Zhang X; Liu S; Xu Y; Wang H; Dai Q; Liu C; Wang X; Yuan Z; Gordeev MF
ACS Med Chem Lett; 2022 Jul; 13(7):1030-1035. PubMed ID: 35859881
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Bulitta JB; Fang E; Stryjewski ME; Wang W; Atiee GJ; Stark JG; Hafkin B
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140023. PubMed ID: 38415667
[TBL] [Abstract][Full Text] [Related]
6. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
Wang W; Li Z; Gordeev MF; Yuan H
J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
[TBL] [Abstract][Full Text] [Related]
7. Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.
Guo Y; Han R; Zhang G; Yang Q; Xue F; Li Y; Zhu D; Hu F
J Antimicrob Chemother; 2023 Apr; 78(4):1055-1058. PubMed ID: 36849586
[TBL] [Abstract][Full Text] [Related]
8. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections.
Zhao X; Huang H; Yuan H; Yuan Z; Zhang Y
J Antimicrob Chemother; 2022 May; 77(6):1762-1769. PubMed ID: 35265985
[TBL] [Abstract][Full Text] [Related]
9. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
10.
Wang S; Cai C; Shen Y; Sun C; Shi Q; Wu N; Zheng S; Qian J; Zhang R; Zhou H
Front Microbiol; 2021; 12():729900. PubMed ID: 34489919
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
12.
Barman TK; Kumar M; Mathur T; Namba E; Singh D; Chaira T; Kurosaka Y; Yamada M; Upadhyay DJ; Masuda N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610202
[TBL] [Abstract][Full Text] [Related]
13. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.
Zhang GX; Liu TT; Ren AX; Liang WX; Yin H; Cai Y
Infection; 2024 Jun; 52(3):787-800. PubMed ID: 38717734
[TBL] [Abstract][Full Text] [Related]
14.
Carvalhaes CG; Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778552
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus.
Oh SH; Park HS; Lee JH; Baek SY; Chae SE; Oh K; Cho YL; Kwak JH
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186032
[No Abstract] [Full Text] [Related]
16. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
[TBL] [Abstract][Full Text] [Related]
17. Contezolid in complicated skin and soft tissue infection.
Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
[TBL] [Abstract][Full Text] [Related]
18. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
19. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Andes D; van Ogtrop ML; Peng J; Craig WA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
Louie A; Liu W; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
